The rapidly aging population, which is the leading cause of prostate cancer, provides an opportunity for the growth of hormone-sensitive prostate cancer.
Prostate cancer is a broad term for a disease in which abnormal cells grow and invade the prostate in an uncontrolled manner. Prostate cancer inhibits the production of male sex hormones (i.e. androgens) and, as a result, blocks androgen action. The androgen is also to blame for the spread of prostate cancer.
Androgen binds to receptors and stimulates the expression of specific genes that cause prostate cancer. Androgen suppression hormonal therapies, on the other hand, are commonly used to treat this cancer. These therapies work by either reducing androgen production by the testicles or by blocking androgen action in the body.
Hormone Sensitive Prostate Cancer Market: Drivers and RestraintsThe rising incidence of hormone-sensitive prostate cancers, as well as the availability of various treatment modalities such as surgery, radiation therapy, and cryosurgery, are the primary factors driving the global growth of the hormone-sensitive prostate cancer treatment market.
The hormone-sensitive prostate cancer market is being driven by the. Other factors expected to boost the global hormone-sensitive prostate cancer treatment market include technological advancements, personalized medicine, and cost-effective treatment procedures.
However, the challenge limiting the growth of the global hormone-sensitive prostate cancer treatment market is the limited commercial availability of drugs and treatments for this cancer.
Hormone Sensitive Prostate Cancer Market: OverviewAndrogen ablation therapy is widely recognized as the first line of treatment and is thus expected to account for the majority of revenue in the overall hormone-sensitive prostate cancer treatment market. Long-term use of anti-androgens and GnRH antagonists is common, which is expected to boost the market for hormone-sensitive prostate cancer.
The rising number of prostate cancer cases drives up demand for hormonal therapies during the forecast period, promoting the market growth.
Hormone Sensitive Prostate Cancer Market: Regional OverviewNorth America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, the Middle East, and Africa account for the majority of the global hormone-sensitive prostate cancer market. North America is the global leader in hormone-sensitive cancer treatment, followed by Europe.
As multinational corporations increase their investment in cancer research, the global hormone-sensitive prostate cancer treatment market is expected to grow in the future.
Hormone Sensitive Prostate Cancer Market: Key PlayersNovartis Pharmaceuticals, Merc & Co., Inc., Bristol-Myers, Dendreon Corporation, GlaxoSmithKline plc., Ferring International Center S.A., Roche group, Celgene Corporation, Amgen Inc., Teva Pharmaceutical Industries Ltd., Bayer AG, and Pfizer Inc. are some of the key players in the hormone-sensitive prostate cancer market.
Hormone Sensitive Prostate Cancer Market: SegmentationThe global hormone-sensitive prostate cancer market has been segmented based on treatment, end-use, and geography.
Based on treatment, the global hormone-sensitive prostate cancer market is segmented into:
- Androgen Ablation Therapy
- Anti-androgens
- Chemotherapy
- Targeted Therapy
- Cryotherapy
Based on end-user type, the global hormone-sensitive prostate cancer market is segmented into:
- Hospitals
- Clinics
- Cancer Rehabilitation Centers
For Critical Insights, Get a Sample Copy
